<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:protege="http://protege.stanford.edu/plugins/owl/protege#" xmlns:xsp="http://www.owl-ontologies.com/2005/08/07/xsp.owl#" xmlns:Thesaurus="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>Assessing Essentiality Leishmania donovani Nitroreductase and <br /> Its Role Nitro Drug Activation <br /> Susan Wyllie, Stephen Patterson, Alan H. Fairlamb <br /> Division Biological Chemistry Drug Discovery, Wellcome Trust Biocentre, College Life Sciences, University Dundee, Dundee, Scotland, United Kingdom <br />  <br /> The nitroimidazole fexinidazole potential safe effective oral drug therapy treatment visceral leishmaniasis. <br /> <span id='am-2' about='protege:TO' typeof='owl:Thing'>To</span> date, nitroheterocyclics used treatment leishmaniasis, relatively little known mecha- <br /> nism action. In African trypanosomes, nitro drugs reductively activated type I nitroreductase (NTR), absent mam- <br /> malian cells. Modulation nitroreductase levels Trypanosoma brucei directly affected sensitivity nitro compounds, with <br /> reduced concentrations enzyme leading moderate nitro drug resistance. In view progression fexinidazole into <br /> clinical development visceral leishmaniasis, assess essentiality nitroreductase Leishmania donovani and <br /> the effect modulating nitroreductase levels susceptibility fexinidazole. The failure directly replace endogenous <br /> copies NTR gene, presence ectopic copy gene, suggests NTR gene essential the <br /> growth <span id='am-3' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-4' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-5' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-6' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-7' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-8' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-9' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-10' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-11' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-12' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-13' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-14' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-15' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-16' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-17' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-18' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-19' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-20' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-21' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-22' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-23' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-24' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-25' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-26' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-27' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-28' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-29' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-30' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-31' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-32' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-33' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-34' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-35' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-36' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-37' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-38' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-39' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-40' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-41' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-42' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-43' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-44' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-45' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-46' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-47' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-48' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-49' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-50' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-51' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-52' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-53' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-54' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-55' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-56' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-57' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-58' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-59' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-60' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-61' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-62' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-63' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-64' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-65' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-66' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-67' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-68' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-69' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-70' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-71' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-72' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-73' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-74' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-75' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-76' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-77' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-78' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-79' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-80' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span>survival</span> L. donovani promastigotes. Loss single chromosomal copy L. donovani NTR gene resulted in <br /> parasites mildly resistant (&lt;2-fold) predominant vivo metabolite fexinidazole, parasites overexpress- <br /> ing NTR 18-fold susceptible. These data confirm Leishmania NTR plays pivotal role fexinidazole activation. <br /> Reliance single enzyme prodrug activation leave fexinidazole vulnerable emergence drug resistance. How- <br /> ever, essentiality NTR L. donovani promastigotes, combined limited resistance shown NTR single <br /> <span id='am-159' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-160' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-161' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-162' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-163' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-164' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-165' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-166' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-167' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-168' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-169' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-170' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-171' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-172' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-173' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-174' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-175' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-176' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-177' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-178' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-179' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-180' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-181' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-182' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-183' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-184' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-185' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-186' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-187' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-188' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-189' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-190' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-191' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-192' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-193' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-194' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-195' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-196' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-197' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-198' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-199' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-200' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-201' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-202' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-203' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-204' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-205' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-206' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-207' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-208' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-209' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-210' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-211' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-212' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-213' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-214' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-215' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-216' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-217' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-218' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-219' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-220' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-221' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-222' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-223' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-224' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-225' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-226' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-227' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-228' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-229' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-230' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-231' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-232' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-233' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-234' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-235' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-236' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span>knockout</span> cells, suggests potential spread NTR-based resistance fexinidazole limited. <br />  <br />  <br />  <br /> V    isceral leishmaniasis (VL), caused protozoan parasite <br />      Leishmania donovani, second largest parasitic killer after <br /> malaria, 200 million people currently risk <span id='am-1' about='protege:FROM' typeof='owl:Thing'>from</span> <br />                                                                                      zole successfully completed, phase II/III trials are <br />                                                                                      scheduled later year (7). Fexinidazole potential as <br />                                                                                      safe effective oral drug therapy treatment visceral <br /> infection. In 95% cases, death prevented timely                     leishmaniasis (8). Administration once-daily oral regimen of <br /> appropriate drug therapy (1); however, current treatment options                     200 mg fexinidazole kg body weight&#226;&#171;&#186;1 5 days found <br /> are far ideal. In India, Bangladesh, Nepal, epicenter                   suppress infection mouse model visceral leishmaniasis by <br /> of VL infection, 60% world&#226;&#8364;&#8482;s reported cases (2), con-                    98.4%, potency comparable seen current front- <br /> certed efforts eradicate disease 2015. At                   line antileishmanial miltefosine. In light findings, fexini- <br /> present, best available treatments anthroponotic VL                      dazole scheduled enter phase II clinical trials the <br /> miltefosine liposomal amphotericin B. Undoubtedly,                          treatment visceral leishmaniasis Sudan (Bernard P&#195;&#169;coul, <br /> drugs vastly superior previous therapies,                  DNDi, personal communication). <br /> limitations. The principal drawbacks miltefosine terato-                      Nitroheterocyclics used treatment of <br /> genicity, prolonged treatment regimen, high resistance po-                       leishmaniasis, result, relatively little known their <br /> tential (3). Problems associated amphotericin B include high                    mechanism action leishmania parasites. In African try- <br /> treatment costs, intravenous route administration, un-                     panosomes, mode action nifurtimox involves reductive <br /> responsiveness Sudanese VL patients (4). Thus, re-                     activation type I NADH-dependent nitroreductase (NTR), <br /> mains definite urgent need strengthen range treat-                   resulting generation cytotoxic, unsaturated open-chain <br /> ment options VL.                                                                 nitrile derivative (9). Overexpression leishmanial homolog <br />     In search more-effective treatments neglected dis-                   nitroreductase L. donovani increase sensi- <br /> eases, renewed chemotherapeutic                       tivity fexinidazole 15-fold sensitivity nifurtimox 19-fold <br /> potential nitroheterocyclic compounds. This stems                        (8), indicating similar mechanisms involved L. <br /> largely success nifurtimox-eflornithine combination                      donovani African trypanosome, Trypanosoma brucei. Ge- <br /> therapy (NECT) treatment Gambian form human                        netic studies indicate nitroreductase essential sur- <br /> African trypanosomiasis (HAT) (5). Treatment NECT, con-                         vival African trypanosome vitro (10). However, modula- <br /> sisting oral nifurtimox 10 days eflornithine infusions <br /> for 7 days, resulted cure rates ca. 97%, leading its <br /> inclusion Essential Medicines List WHO (5). The                           Received 29 August 2012 Returned modification 11 October 2012 <br /> success nifurtimox NECT prompted Drugs                            Accepted 26 November 2012 <br /> Neglected Diseases Initiative (DNDi) undertake comprehen-                          Published ahead print 3 December 2012 <br /> sive screen 700 nitroheterocyclic compounds antiparasitic                        Address correspondence Susan Wyllie, s.wyllie@dundee.ac.uk. <br /> activity. As result, 2-substituted 5-nitroimidazole fexinida-                     Copyright &#194;&#169; 2013, American Society Microbiology. All Rights Reserved. <br /> zole (Hoe 239), shown antitrypanosomal activity al-                       doi:10.1128/AAC.01788-12 <br /> most 30 years ago (6), rediscovered. Subsequently, phase I                          The authors paid fee allow immediate free access article. <br /> clinical trials treating African sleeping sickness fexinida- <br />  <br />  <br /> February 2013 Volume 57 Number 2                                  Antimicrobial Agents Chemotherapy         p. 901&#226;&#8364;&#8220;906                                 aac.asm.org   901 <br />  Wyllie et al. <br />  <br />  <br />  <br /> tion nitroreductase levels trypanosomatids             TABLE 1 Cloning primers <br /> shown directly affect sensitivity nitro compounds vitro,             Primer                    Primer sequencea <br /> with reduced enzyme activity leading moderate nitro drug re-               5=UTR-NotI_s          5=-ataagaatgcggccgcAGTCATGTGATGGTG <br /> sistance (10). In view progression fexinidazole clin-                                   GTTTACGGCA-3= <br /> ical development visceral leishmaniasis, clear po-         5=UTR-HindIII/PmeI_as 5=-gtttaaacttacggaccgtcaagcttTGTAGTTTCT <br /> tential nitroreductase-mediated drug resistance                                     CTTGCTGCTTTCC-3= <br /> addressed Leishmania spp. With mind, assess               3=UTR-PmeI/BamHI_s 5=-gacggtccgtaagtttaaacggatccTTTAGACTCG <br /> the essentiality nitroreductase Leishmania donovani                                      GCACCAGAGATGAGA-3= <br /> the effect modulation nitroreductase levels suscepti-            3=UTR-NotI_as         5=-ataagtaagcggccgcCCAAGACAGCAGCA <br /> bility nitro drugs.                                                                                 GCCGGTCGTGA-3= <br />                                                                               LdNTR-BamHI_s         5=-ggatccATGCTTCGCCGCAGTCGCCGCTT-3= <br />                                                                               LdNTR-BamHI_as        5=-ggatccTAGAACTTGTTCCACCGCACGGT-3= <br /> MATERIALS AND METHODS                                                         a <br />                                                                                 Capital letters represent nucleotides corresponding gene sequences L. infantum; <br /> Ethics statement. All animal experiments approved Ethical         lowercase letters represent additional sequences used generating constructs. <br /> Review Committee University Dundee performed un-           Restriction endonuclease sites underlined. <br /> der Animals (Scientific Procedures) Act 1986 (United Kingdom Home <br /> Office Project License PPL 60/4039) accordance European <br /> Communities Council Directive (86/609/EEC). <br />     Cell lines culture conditions. The clonal Leishmania donovani              The recovery vector generated amplifying LdBOB nitrore- <br /> cell line LdBOB (derived MHOM/SD/62/1S-CL2D) grown                ductase gene genomic DNA using LdNTR-BamHI sense and <br /> promastigotes 26&#194;&#176;C modified M199 medium, described previously        antisense primers. The PCR product cloned pCR-Blunt <br /> (11).                                                                         II-TOPO vector (Invitrogen) sequenced. The pCR-Blunt II- <br />     Test compounds. Fexinidazole sulfone synthesized described         TOPO-LdNTR construct digested BamHI, frag- <br /> previously (8). Compound purity determined liquid chromatog-           ment cloned pIR1SAT expression vector (14), resulting a <br /> raphy&#226;&#8364;&#8220;mass spectrometry (LC-MS) &#226;&#177;&#8211;95%. The                 pIR1SAT-LdNTR construct. <br /> stocks nifurtimox used study provided Bayer, Argentina,         Generation LdBOB transgenic cell lines. Mid-log-phase L. don- <br /> as kind gift. Nitrofurazone miltefosine purchased Sigma-      ovani promastigotes (LdBOB) transfected knockout or <br /> Aldrich Ltd.                                                                  recovery constructs using Human T-Cell Nucleofector kit the <br />     In vitro drug sensitivity assays. To examine effects test com-     Amaxa Nucleofector electroporator (program V-033). Following trans- <br /> pounds growth, triplicate promastigote cultures seeded 1 &#226;&#171;&#187;       fection, cells allowed grow 16 24 h modified M199 me- <br /> 105 parasites ml&#226;&#171;&#186;1. Parasites grown 5-ml cultures presence     dium (11) 10% fetal calf serum prior appropriate drug selection <br /> of drug 72 h, 200-&#226;?&#174;l aliquots culture added    (100 &#226;?&#174;g nourseothricin ml&#226;&#171;&#186;1, 50 &#226;?&#174;g hygromycin ml&#226;&#171;&#186;1, 20 &#226;?&#174;g puro- <br /> to 96-well plates; 50 &#226;?&#174;M resazurin added well; fluores-       mycin ml&#226;&#171;&#186;1). Cloned cell lines generated limiting dilution, main- <br /> cence (excitation wavelength, 528 nm; emission wavelength, 590 nm)        tained selective medium, removed drug selection one <br /> measured 4 h incubation (12). Data processed using    passage prior experiments. <br /> GRAFIT (version 5.0.4; Erithacus Software) fitted 2-param-           Southern blot analyses transgenic L. donovani cell lines. The ORF <br /> eter equation, data corrected background fluorescence,      5= UTR LdBOB NTR amplified PCR (using primers <br /> to obtain effective concentration inhibiting growth 50% (EC50):        listed Table 1 cloning L. donovani NTR [LdNTR] knock- <br />                                     100                                       constructs) PCR DIG Probe Synthesis kit (Roche). The re- <br />  <br />                                       &#229;&#8224;&#8240; &#229;&#8224;&#352; <br />                           y &#226;&#171;&#189;                                                 sulting digoxigenin (DIG)-labeled products used probes. Samples <br />                                       &#229;&#8230;&#179;I&#229;&#8230;&#180;     m <br />                                                                               genomic DNA (5 &#226;?&#174;g) wild-type (WT) transgenic cell lines <br />                                 1 &#226;&#171;&#185; <br />                                      EC50                                     digested appropriate restriction endonucleases, diges- <br /> In equation, [I] represents inhibitor concentration m     tion products separated 0.8% agarose gel trans- <br /> slope factor. The experiments repeated times,     ferred positively charged nylon membrane (Roche). The membrane <br /> data presented weighted means plus weighted standard devia-        hybridized overnight DIG Easy Hyb solution (Roche) 42&#194;&#176;C with <br /> tions (12).                                                                   DIG-labeled TRYS ORF 5= UTR probes (2 &#226;?&#174;l PCR product). <br />     Amastigote drug sensitivity assays. In-macrophage drug sensitivity        Following hybridization, membranes washed twice low-strin- <br /> assays carried described previously (8), using starch-elicited    gency conditions (25&#194;&#176;C, 5 min, SSC 0.1% sodium dodecyl sulfate <br /> peritoneal macrophages harvested BALB/c mice. Macrophages           [SDS]) twice high-stringency conditions (68&#194;&#176;C, 15 min, 0.5&#226;&#171;&#187; <br /> infected metacyclic promastigotes ratio 10 promastigotes 1    SSC 0.1% SDS), 1&#226;&#171;&#187; SSC comprises 150 mM sodium chloride <br /> macrophage.                                                                   50 mM sodium citrate (pH 7.0). Bound probe detected using <br />     Generation knockout, overexpression, recovery constructs.          DIG immunological detection kit (Roche) according manufac- <br /> The primers used generate constructs genetic manipulation         turer&#226;&#8364;&#8482;s instructions. <br /> designed using Leishmania infantum nitroreductase (NTR) sequence               Northern blot analyses transgenic L. donovani cell lines. Total <br /> in GeneDB (LinJ.05.0660) template (Table 1). The accuracy         RNA isolated mid-log-phase L. donovani (LdBOB) promasti- <br /> constructs assembled verified sequencing. NTR gene replacement         gotes (1 &#226;&#171;&#187;108) using RNeasy Plus kit (Qiagen). Northern blot <br /> cassettes generated amplifying region DNA encompassing       analysis RNA samples carried separating RNA (10 &#226;?&#174;g) a <br /> 5= untranslated region (5= UTR), open reading frame (ORF), 3= UTR         1% (wt/vol) agarose-formaldehyde gel transferring RNA a <br /> of LdBOB NTR genomic DNA primers 5=UTR-NotI_s                   positively charged nylon membrane (Roche). The membrane hybrid- <br /> 3=UTR-NotI_as, using Pfu polymerase. This sequence used         ized overnight DIG Easy Hyb solution (Roche) 68&#194;&#176;C DIG- <br /> template amplification individual regions used assem-   labeled NTR RNA probe, generated NTR ORF using DIG <br /> bly replacement cassettes containing selectable drug resistance        Northern starter kit (Roche). Following hybridization, membranes were <br /> genes encoding puromycin N-acetyltransferase (PAC) hygromycin             washed, bound probe detected manner identical that <br /> phosphotransferase (HYG), constructed exactly described previously         described Southern blots. Levels NTR transcripts cell <br /> (13).                                                                         line directly compared densitometry using ImageJ program. <br />  <br />  <br /> 902 aac.asm.org                                                                                                           Antimicrobial Agents Chemotherapy <br />                                                                                                                 Essentiality Leishmania donovani Nitroreductase <br />  <br />  <br />  <br />  <br />                                                                                   FIG 2 Analysis NTR transcript levels Northern blotting. (A) RNA sam- <br />                                                                                   ples (10 &#226;?&#174;g) prepared WT (lane 1), SKO (lane 2), OE (lane 3) <br />                                                                                   promastigotes analyzed Northern blotting. Blots hybridized <br />                                                                                   RNA probe generated LdBOB NTR gene. (B) Ethidium bro- <br />                                                                                   mide staining RNA samples loaded agarose-formaldehyde gel prior to <br />                                                                                   transfer. <br />  <br />  <br />  <br />  <br />                                                                                   replacing second copy PAC. This ectopic copy NTR <br />                                                                                   inserted ribosomal DNA (rDNA) locus SKO <br />                                                                                   cell line using pIR1SAT vector, encodes a <br /> FIG 1 Genotypic analysis WT, SKO, rDKO cell lines. (A) Southern blot       nourseothricin resistance gene (SAT), resulting constitutive <br /> analysis SalI-digested genomic DNA (&#226;&#172;&#402;5 &#226;?&#174;g) wild-type L. donovani          expression NTR. All clones rDKO promastigotes con- <br /> (LdBOB) cells (lane 1), NTR single knockout (HYG) cells (lane 2), NTR single      firmed Southern blotting lost copies en- <br /> knockout (HYG) cells constitutively expressing NTR (lane 3), NTR double           dogenous NTR genes (Fig. 1A). Our failure directly replace both <br /> knockout (PAC HYG) cells constitutively expressing NTR (lane 4), and <br />                                                                                   endogenous copies NTR, presence ecto- <br /> &#226;&#8364;&#339;false&#226;&#8364;? NTR double knockout (PAC HYG) cells (lanes 5 7). The NTR <br /> ORF probe shows allelic LdNTR 6.5 kb, ectopic copy LdNTR &#226;&#172;&#402;9 kb,      pic copy gene, strongly suggests NTR gene essen- <br /> and chromosomally rearranged copy NTR 5.5 kb (*). (B) Southern blot       tial successful growth survival L. donovani promas- <br /> analysis NotI-digested genomic DNA (&#226;&#172;&#402;5 &#226;?&#174;g) wild-type L. donovani          tigotes culture. <br /> (LdBOB) cells (lane 1) NTR single knockout (HYG) cells (lane 2) probed            Modulation NTR levels L. donovani alters sensitivity to <br /> with 5= UTR NTR. (C) Structure NTR locus NTR single knock- <br /> out (HYG) cells. Black bars represent 5= UTR region upstream open      nitro drugs. Modulation nitroreductase levels Trypano- <br /> reading frame NTR, used probe Southern blot analysis.        soma brucei Trypanosoma cruzi shown directly <br /> NotI sites expected fragment sizes shown. The endogenous NTR gene        affect sensitivity nitro compounds vitro, reduced con- <br /> contains NotI site results 2-kb band. Successful replacement   centrations enzyme leading nitro drug resistance (10). To <br /> allelic copy endogenous gene HYG, does contain NotI <br /> site, results 9-kb fragment. <br />                                                                                   determine case L. donovani, sensi- <br />                                                                                   tivities WT, SKO, NTR-overexpressing (OE) promasti- <br />                                                                                   gotes number nitroheterocyclic compounds assessed. <br />                                                                                   First, modulation NTR transgenic cell lines con- <br /> RESULTS                                                                           firmed comparing NTR transcript levels Northern blotting <br /> Generation NTR-complemented <span id='am-81' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-82' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-83' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-84' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-85' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-86' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-87' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-88' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-89' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-90' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-91' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-92' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-93' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-94' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-95' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-96' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-97' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-98' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-99' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-100' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-101' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-102' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-103' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-104' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-105' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-106' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-107' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-108' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-109' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-110' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-111' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-112' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-113' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-114' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-115' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-116' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-117' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-118' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-119' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-120' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-121' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-122' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-123' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-124' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-125' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-126' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-127' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-128' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-129' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-130' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-131' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-132' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-133' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-134' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-135' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-136' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-137' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-138' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-139' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-140' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-141' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-142' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-143' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-144' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-145' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-146' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-147' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-148' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-149' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-150' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-151' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-152' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-153' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-154' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-155' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-156' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-157' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-158' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span>null mutants</span>. The essential-                       (Fig. 2). NTR transcript levels 1.7-fold lower SKO parasites <br /> ity L. donovani nitroreductase assessed classical gene                  4.2-fold higher OE parasites WT parasites, de- <br /> replacement, NTR sequentially replaced drug resis-                  termined densitometry. As expected, changes level of <br /> tance genes. The copy NTR gene replaced                 NTR cells correlated directly relative sensitivi- <br /> hygromycin resistance gene (HYG, encoding hygromycin phos-                        ties nifurtimox nitrofurazone, nitrofuran compounds <br /> photransferase) homologous recombination subsequent                        known undergo NTR-catalyzed 2-electron reduction try- <br /> selection hygromycin resistance, generating single knockout                 panosomes (Table 2). Promastigotes overexpressing NTR were <br /> (SKO) cell line (Fig. 1A B). SKO promastigotes grew                    16- 4-fold sensitive WT cells nifur- <br /> same rate culture homozygotes, cell density.                timox nitrofurazone, respectively. Conversely, SKO parasites <br /> Attempts create null mutant directly re-                   sensitive compounds, EC50s 7.2 2.5 <br /> placing second allelic copy puromycin N-acetyltrans-                 &#226;?&#174;M nifurtimox nitrofurazone, respectively, compared to <br /> ferase gene (PAC). On separate occasions, promastigotes re-                  values 5.0 1.4 &#226;?&#174;M WT cells. Similar NTR level-depen- <br /> sistant hygromycin puromycin recovered                      dent shifts sensitivity observed cells treated fexini- <br /> transfections. However, Southern blot analysis genomic DNA                     dazole sulfone, predominant active metabolite nitroim- <br /> from multiple clones putative double knockout (DKO)                      idazole fexinidazole vivo (8, 15). While parasites overexpressing <br /> cells revealed retained endogenous copy                  NTR 18-fold susceptible fexinidazole sulfone than <br /> NTR generated additional gene copy, presumably                    WT parasites, SKO promastigotes marginally sensitive <br /> by chromosomal rearrangement (Fig. 1A). Consequently, res-                      (&#226;&#172;?2-fold [Table 2]). In contrast, concomitant shift in <br /> cued double knockout (rDKO) cell line generated intro-                     sensitivity promastigotes alkyl phospholipid milte- <br /> ducing ectopic copy NTR SKO promastigotes prior                     fosine. Thus, NTR plays crucial role activation fexini- <br />  <br />  <br /> February 2013 Volume 57 Number 2                                                                                                               aac.asm.org 903 <br />  Wyllie et al. <br />  <br />  <br />  <br /> TABLE 2 Sensitivities WT, SKO, OE promastigotes standard drugs experimental nitro compounds <br />                                                                                         EC50a (Hill slope) L. donovani <br /> Compound                                Structure                                       WT                                OE                              SKO <br />  <br />  <br /> Fexinidazole sulfone                                                                    7.2 &#226;&#171;&#190; 0.2 (5.4)                   0.4 &#226;&#171;&#190; 0.01b (2.3)               12.6 &#226;&#171;&#190; 0.1b (2.3) <br />  <br />  <br />  <br /> Nifurtimox                                                                              5.0 &#226;&#171;&#190; 0.05 (4.7)                  0.32 &#226;&#171;&#190; 0.01b (2.8)              7.23 &#226;&#171;&#190; 0.08b (2.5) <br />  <br />  <br />  <br /> Nitrofurazone                                                                           1.43 &#226;&#171;&#190; 0.02 (5.5)                 0.35 &#226;&#171;&#190; 0.01b (2.4)              2.5 &#226;&#171;&#190; 0.02b (2.5) <br />  <br />  <br /> Miltefosine                                                                             7.7 &#226;&#171;&#190; 0.1 (3.5)                   8.16 &#226;&#171;&#190; 0.05 (3.8)               7.9 &#226;&#171;&#190; 0.2 (3.3) <br />  <br /> a <br />     Expressed micromolar concentrations. Results weighted means standard errors independent experiments. <br /> b <br />     P, &#226;&#172;?0.0001 comparison WT Student&#226;&#8364;&#8482;s t test. <br />  <br />  <br />  <br /> dazole metabolites L. donovani, NTR depletion <br /> within cells lead minor levels resistance promastigotes. <br />     NTR modulation intracellular amastigotes. In manner <br /> identical seen insect-stage promastigotes, potency <br /> of fexinidazole sulfone intracellular mammalian-stage amasti- <br /> gotes materially altered changes cellular NTR levels. <br /> Metacyclic promastigotes (WT, SKO, OE) used infect <br /> starch-elicited mouse peritoneal macrophages, EC50s were <br /> determined cell line following 72-h incubation vary- <br /> ing concentrations drug (Fig. 3A). Intracellular amastigotes <br /> overexpressing NTR approximately 9-fold sensitive to <br /> fexinidazole sulfone (EC50, 0.7 &#226;?&#174;M) WT parasites (EC50, 6.4 <br /> &#226;?&#174;M), SKO parasites showed &#226;&#172;?2-fold decrease sensitiv- <br /> ity drug (EC50, 8.8 &#226;?&#174;M). The finding loss single <br /> copy NTR gene leads fexinidazole resistance L. dono- <br /> vani keeping resistance mechanisms iden- <br /> tified laboratory-generated fexinidazole-resistant T. brucei cell <br /> lines (15). However, noted EC99 fexinida- <br /> zole sulfone intracellular SKO amastigotes (78.5 &#226;?&#174;M), cal- <br /> culated using Hill slopes, markedly different cal- <br /> culated WT amastigotes (69.6 &#226;?&#174;M). <br />     Loss allelic copy NTR did diminish infectivity <br /> of SKO metacyclic promastigotes: mean number amasti- <br /> gotes infected macrophage overall percentage in- <br /> fected macrophages untreated controls comparable to <br /> those seen WT-infected macrophage cultures (Fig. 3B C). <br /> However, parasites overexpressing NTR did appear lose <br /> &#226;&#8364;&#339;fitness.&#226;&#8364;? Both number OE amastigotes infected mac- <br /> rophage percentage macrophages infected OE                              FIG 3 Effects NTR modulation susceptibility fexinidazole sulfone. <br />                                                                                             The susceptibilities amastigotes cultured starch-elicited mouse peritoneal <br /> cell line significantly lower WT (P, 0.04                           macrophages determined. (A) The EC50s fexinidazole sulfone against <br /> and 0.03, respectively).                                                                    WT (open circles), SKO (HYG) (filled circles), OE (open squares) para- <br />                                                                                             sites determined. EC50s 6.4 &#226;&#171;&#190; 0.9, 8.8 &#226;&#171;&#190; 0.7, 0.7 &#226;&#171;&#190; 0.06 &#226;?&#174;M were <br /> DISCUSSION                                                                                  fexinidazole sulfone WT, SKO, OE cell lines, respec- <br />                                                                                             tively. (B) The mean number WT, SKO, OE amastigotes infecting mouse <br /> Our inability knock allelic copies NTR,                        peritoneal macrophages untreated control cultures determined. Differ- <br /> presence ectopic copy gene, provides strong evidence                           ences number WT versus OE amastigotes infecting macrophages were <br /> that endogenous function NTR essential viability                          confirmed statistically significant (P &#226;&#171;&#189; 0.04) using unpaired Student t <br /> of L. donovani promastigotes. This true African                             test (*). (C) The percentage macrophages infected WT, SKO, OE <br />                                                                                             amastigotes untreated control cultures determined. Differences the <br /> trypanosome: NTR deleted bloodstream-form                                 percentage macrophages infected WT versus OE amastigotes were <br /> T. brucei parasites (10). In case South American try-                            confirmed statistically significant (P &#226;&#171;&#189; 0.03) using unpaired Student t <br /> panosome T. cruzi, NTR-null mutants epimastigote (insect                             test (*). All data means triplicate measurements. <br />  <br />  <br />  <br /> 904      aac.asm.org                                                                                                                   Antimicrobial Agents Chemotherapy <br />                                                                                                         Essentiality Leishmania donovani Nitroreductase <br />  <br />  <br />  <br /> stage) unable differentiate infectious metacyclic trypo-     tion, rationale likelihood developing resis- <br /> mastigotes infect mammalian cells (10). Thus, NTR             tance single agent relatively high, likelihood of <br /> activity appears absolute requirement virulence      developing resistance compounds significantly lower <br /> trypanosomatids mammalian hosts. The biological func-           (19). The use drug combinations circumvent resistance <br /> tions trypanosomal NTRs remain determined. However,             successful antimalarials (19), approach <br /> there evidence enzymes play role             seriously considered treatment visceral <br /> ubiquinone metabolism. Trypanosomal NTRs share fea-              leishmaniasis. Indeed, recent trial directly compared effi- <br /> tures mitochondrial NADH dehydrogenases (10), enzymes               cacies potential short-course combination treatments <br /> known catalyze transfer electrons NADH ubiqui-         standard monotherapy India (20). The re- <br /> none, leading generation ubiquinol (16). In addition,        sults study confirm combination treatments <br /> recent genomewide <span id='am-237' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-238' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-239' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-240' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-241' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-242' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-243' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-244' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-245' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-246' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-247' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-248' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-249' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-250' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-251' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-252' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-253' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-254' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-255' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-256' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-257' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-258' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-259' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-260' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-261' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-262' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-263' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-264' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-265' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-266' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-267' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-268' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-269' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-270' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-271' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-272' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-273' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-274' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-275' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-276' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-277' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-278' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-279' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-280' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-281' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-282' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-283' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-284' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-285' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-286' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-287' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-288' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-289' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-290' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-291' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-292' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-293' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-294' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-295' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-296' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-297' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-298' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-299' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-300' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-301' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-302' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-303' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-304' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-305' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-306' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-307' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-308' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-309' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-310' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-311' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-312' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-313' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-314' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span>RNA interference</span> (RNAi) target-sequencing              visceral leishmaniasis efficacious safe well <br /> screen T. brucei demonstrated link nitro drug action,       reduce emergence drug-resistant parasites. With pro- <br /> ubiquinone biosynthesis, nitroreductases (17). While         gression fexinidazole clinical development use <br /> studies required order pinpoint precise essential      visceral leishmaniasis, work identify appropriate <br /> biological function trypanosomal NTRs, clear     partner drug nitroimidazole way. <br /> enzymes play crucial role activation nitro drugs. <br /> The essentiality enzymes &#226;&#8364;&#339;Tritryp&#226;&#8364;? parasites       ACKNOWLEDGMENTS <br /> also makes attractive targets development novel          This work supported grants (079838, 077705, 083481) to <br /> chemotherapeutic agents undergo reductive activa-            A.H.F. Wellcome Trust (http://www.wellcome.ac.uk). <br /> tion. <br />     Loss single chromosomal copy L. donovani NTR             REFERENCES <br /> gene resulted parasites mildly resistant ni-      1. Ritmeijer K, Davidson RN. 2003. Medecins Sans Fronti&#195;&#168;res interventions <br /> troheterocyclic compounds, including predominant vivo                 kala-azar Sudan, 1989 &#226;&#8364;&#8220;2003. Trans. R. Soc. Trop. Med. Hyg. <br /> metabolite antileishmanial drug candidate fexinidazole.               97:609 &#226;&#8364;&#8220; 613. <br /> These data, combined pronounced hypersensitivity dem-            2. Regional Technical Advisory Group Kala-azar Elimination. 2005. <br />                                                                              Report meeting, Manesar, Haryana, 20 &#226;&#8364;&#8220;23 December 2004. <br /> onstrated promastigotes overexpressing NTR, confirm the <br />                                                                              WHO project IND CDR 714. SEA-VBC-88. World Health Organization <br /> Leishmania NTR plays pivotal role activation nitro               Regional Office South-East Asia, New Delhi, India. http://www.searo <br /> drugs general, mechanism action fexinidazole          .who.int/LinkFiles/Kala_azar_VBC-88.pdf. <br /> particular. Recent studies shown trypanosomal nitrore-          3. den Boer ML, Alvar J, Davidson RN, Ritmeijer K, Balasegaram M. 2009. <br /> ductases catalyze sequential 2-electron reduction nifurti-            Developments treatment visceral leishmaniasis. Expert Opin. <br />                                                                              Emerg. Drugs 14:395&#226;&#8364;&#8220; 410. <br /> mox, resulting generation cytotoxic, unsaturated open-        4. Mueller M, Ritmeijer K, Balasegaram M, Koummuki Y, Santana MR, <br /> chain nitrile derivative (9). It remains seen                  Davidson R. 2007. Unresponsiveness AmBisome Sudanese <br /> fexinidazole metabolites undergo similar 2-electron re-            patients kala-azar. Trans. R. Soc. Trop. Med. Hyg. 101:19 &#226;&#8364;&#8220;24. <br /> duction catalyzed Leishmania nitroreductase. Importantly,          5. Priotto G, Kasparian S, Mutombo W, Ngouama D, Ghorashian S, <br />                                                                              Arnold U, Ghabri S, Baudin E, Buard V, Kazadi-Kyanza S, Ilunga M, <br /> these findings illustrate mechanism clinical resis- <br />                                                                              Mutangala W, Pohlig G, Schmid C, Karunakara U, Torreele E, Kande <br /> tance fexinidazole emerge. Reliance single enzyme              V. 2009. Nifurtimox-eflornithine combination therapy second-stage <br /> for prodrug activation leave drugs fexinidazole vul-             African Trypanosoma brucei gambiense trypanosomiasis: multicentre, <br /> nerable emergence drug resistance. However, failure            randomised, phase III, non-inferiority trial. Lancet 374:56 &#226;&#8364;&#8220; 64. <br /> to generate NTR-null promastigotes clearly suggests         6. Jennings FW, Urquhart GM. 1983. The use 2 substituted 5-nitro- <br />                                                                              imidazole, Fexinidazole (Hoe 239) treatment chronic T. brucei <br /> selective pressure Leishmania parasites retain NTR               infections mice. Z. Parasitenkd. 69:577&#226;&#8364;&#8220;581. <br /> activity. This pressure added advantage limiting          7. Torreele E, Trunz BB, Tweats D, Kaiser M, Brun R, Mazue G, Bray MA, <br /> the maximum levels fexinidazole resistance achievable,               Pecoul B. 2010. Fexinidazole&#226;&#8364;&#8221;a new oral nitroimidazole drug candidate <br /> SKO promastigotes 2-fold resistant drug. In            entering clinical development treatment sleeping sickness. PLoS <br />                                                                              Negl. Trop. Dis. 4:e923. doi:10.1371/journal.pntd.0000923. <br /> recent studies T. cruzi, laboratory-generated benznidazole- <br />                                                                           8. Wyllie S, Patterson S, Stojanovski L, Simeons FR, Norval S, Kime R, <br /> resistant parasites lost single copy NTR         Read KD, Fairlamb AH. 2012. The anti-trypanosome drug fexinidazole <br /> gene, mutations arising remaining copy gene                shows potential treating visceral leishmaniasis. Sci. Transl. Med. <br /> abolished enzyme activity (18). However, &#226;&#8364;&#339;functional null&#226;&#8364;?             4:119re1. doi:10.1126/scitranslmed.3003326. <br /> parasites demonstrated reduced levels virulence          9. Hall BS, Bot C, Wilkinson SR. 2011. Nifurtimox activation trypano- <br />                                                                              somal type I nitroreductases generates cytotoxic nitrile metabolites. J. <br /> capacity highly drug resistant T. cruzi parasites spread         Biol. Chem. 286:13088 &#226;&#8364;&#8220;13095. <br /> within population severely compromised. At           <br /> </body></html>